PartnershipUpdated on 14 July 2025
HOIST Corp. Ltd. seeks to license-out rights for HM-001 and ALKBH3 inhibitor
About
HOIST Corp. Ltd. is a clinical-stage biotechnology company founded in 2019 based on discoveries from The University of Osaka.
HOIST Corp. is currently seeking partners to further develop our programs: HM-001 for bladder cancer (non-muscle invasive bladder cancer), and ALKBH3 inhibitor, currently in the pre-clinical stage for pancreatic cancer.
HM-001 completed the Phase I portion of the Phase I/IIa clinical study, and is on schedule to initiate the Phase II portion of the study in 2H 2025.
ALKBH3 inhibitor will be a molecular targeting drug with a new mode-of-action for cancer type with one of the biggest unmet needs: pancreatic cancer.
We would be pleased to discuss our programs in more detail at the event.
Organisation
Similar opportunities
Project cooperation
SSO-001 for Osteoarthritis (OA)
- Research
- Execution
- Technical
- Financing
- Sales/Distribution